Fractional Head of Translational Medicine & Biomarker Strategy
Helping oncology biotechs de-risk First-in-Human studies, avoid CRO failures and turn biomarker data into decisions.

Helping oncology biotechs de-risk First-in-Human studies, avoid CRO failures and turn biomarker data into decisions.

Best for: Seed to Series B biotechs preparing for FiH or running Phase I/II trials without a full-time VP/Head of Translational Medicine.
What you get: Embedded executive leadership (1–2 days/week) owning your translational strategy, cross-functional alignment (Discovery, Preclinical, Clinical, CMC), and board/investor scientific updates.
Best for: Teams selecting bioanalytical labs, preparing clinical site workflows, or transferring assays to external vendors.
What you get: GxP-compliant analytical vendor selection (RFI/RFP), technical lab audits, assay transfer oversight, and bulletproof Clinical Laboratory Manuals- preventing sample loss and multi-platform blind spots before patient specimens are at risk.
Best for: Teams preparing regulatory briefing packages, clinical protocols, or upcoming fundraising rounds.
What you get: Authoring translational and biomarker sections for clinical protocols (including Schedule of Assessments) and ICFs, defining pharmacodynamic sampling strategies, and providing cross-functional scientific review of Pre-IND/CTA packages and investor data rooms.
Translational Strategy • Biomarker Strategy • Early Clinical Development • CRO & Vendor Oversight • Assay Strategy • Data-Driven Decision Support
Many development programmes generate large volumes of data. Far fewer generate true understanding.
I help teams connect disease biology, drug mechanism, patient heterogeneity and clinical outcomes into a coherent translational strategy.
My strength lies in recognising patterns, identifying missing links, and uncovering opportunities that may be overlooked when scientific disciplines operate in isolation.
By integrating evidence from pathology, immunology, flow cytometry, multi-omics and clinical data, I help organisations understand not only what is happening, but why it is happening. This approach enables the identification of mechanisms of response and resistance, patient stratification opportunities, and translational insights that support confident clinical decision-making.
I am known for asking unconventional questions and challenging assumptions that may otherwise go untested. Often, the most valuable insight is not found in the data itself, but in recognising what has not yet been explored.
The most valuable answers often come from the questions nobody thought to ask.
✅ Cell Therapies
✅ Microbial Therapies
✅ Targeted Protein Degraders
✅ Immune Checkpoint Inhibitors
✅ Combination Therapies
AML • MDS • Lymphoma • Multiple Myeloma
• Melanoma • NSCLC • NMIBC • HCC • PDAC • Breast Cancer • Ovarian Cancer • Synovial Sarcoma